Influenza virus and Epstein-Barr virus peptides
| CEF product | Peptide sequence | Catalog no. | Quantity | GBP |
| CEF1, Influenza Matrix Protein M1 (58 – 66) | GILGFVFTL | AB-CEF001 | 1 mg | £105 |
| CEF2, Influenza Virus PA (46 – 54) | FMYSDFHFI | AB-CEF002 | 1 mg | £105 |
| CEF3, Influenza Virus M1 (13 – 21) | SIIPSGPLK | AB-CEF003 | 1 mg | £105 |
| CEF4, Influenza Virus NP (342 – 351) | RVLSFIKGTK | AB-CEF004 | 1 mg | £105 |
| CEF5, Influenza Virus NP (91 – 99) | KTGGPIYKR | AB-CEF005 | 1 mg | £105 |
| CEF6, Influenza Virus NP | LPFDKTTVM | AB-CEF006 | 1 mg | £105 |
| CEF7, Influenza Virus NP (380 – 388) | ELRSRYWAI | AB-CEF007 | 1 mg | £105 |
| CEF8, Influenza Virus NP (383 – 391) | SRYWAIRTR | AB-CEF008 | 1 mg | £105 |
| CEF9, Influenza Virus M1 128 – 135 | ASCMGLIY | AB-CEF009 | 1 mg | £105 |
| CEF10, Epstein – Barr Virus LMP2 (426 – 434) | CLGGLLTMV | AB-CEF010 | 1 mg | £105 |
| CEF11, Epstein – Barr Virus BMLF1 (280 – 288) | GLCTLVAML | AB-CEF011 | 1 mg | £105 |
| CEF12, Epstein – Barr Virus latent NA3B (399 – 408), AVF | AVFDRKSDAK | AB-CEF012 | 1 mg | £105 |
| CEF14, Epstein – Barr Virus RTA Protein (28 – 37) | DYCNVLNKEF | AB-CEF014 | 1 mg | £105 |
| CEF15, Epstein – Barr Virus Lytic Cycle Protein BZLF – 1(190 – 197) | RAKFKQLL | AB-CEF015 | 1 mg | £105 |
| CEF16, Epstein – Barr Virus latent NA – 3A (337 – 347) | FLRGRAYGL | AB-CEF016 | 1 mg | £105 |
| CEF17, Epstein – Barr Virus latent NA – 3A (158 – 166) | QAKWRLQTL | AB-CEF017 | 1 mg | £105 |
| CEF18, Epstein – Barr Virus latent NA – 3C (258 – 266) | RRIYDLIEL | AB-CEF018 | 1 mg | £105 |
| CEF19, Epstein – Barr Virus latent NA – 3A (458 – 466) | YPLHEQHGM | AB-CEF019 | 1 mg | £105 |
| CEF20, Cytomegalovirus, CMV pp65 (495 – 503) | NLVPMVATV | AB-CEF020 | 1 mg | £105 |
| CEF21, Cytomegalovirus, CMV pp65 (417 – 426) | TPRVTGGGAM | AB-CEF021 | 1 mg | £105 |
| CEF22, Cytomegalovirus, CMV pp65 (378 – 389) | SDEEEAIVAYTL | AB-CEF022 | 1 mg | £105 |
| CEF23, Cytomegalovirus, CMV pp65 (123 – 131) | IPSINVHHY | AB-CEF023 | 1 mg | £105 |
| CEF24, Influenza Virus PB1 Peptide (591 – 599) | VSDGGPNLY | AB-CEF024 | 1 mg | £105 |
| CEF25, Influenza Virus NP (44 – 52) | CTELKLSDY | AB-CEF025 | 1 mg | £105 |
| CEF26, Influenza Virus NP (265 – 274) | ILRGSVAHK | AB-CEF026 | 1 mg | £105 |
| CEF27, Epstein – Barr Virus BRLF – 1 lytic (148 – 156) | RVRAYTYSK | AB-CEF027 | 1 mg | £105 |
| CEF28, Epstein – Barr Virus latent NA – 3A (603 – 611) | RLRAEAQVK | AB-CEF028 | 1 mg | £105 |
| CEF29, Epstein – Barr Virus latent NA – 3B (416 – 424) | IVTDFSVIK | AB-CEF029 | 1 mg | £105 |
| CEF30, Epstein – Barr Virus BRLF1 (134 – 142) | ATIGTAMYK | AB-CEF030 | 1 mg | £105 |
| CEF31, Epstein – Barr Virus latent NA – 3A (379 – 387) | RPPIFIRRL | AB-CEF031 | 1 mg | £105 |
| CEF32, Epstein – Barr Virus latent NA – 3C (281 – 290) | EENLLDFVRF | AB-CEF032 | 1 mg | £105 |
| CEF33, Cytomegalovirus, HCMV pp65 | EFFWDANDIY | AB-CEF033 | 1 mg | £105 |
Related articles
Fluorescent Peptides: A Guide for Life Science Researchers
Explore key considerations for designing fluorescent peptides, including dye selection, spacers, handling, and storage. Read our guide.
Peptide Synthesis: An Overview
Peptide synthesis is a cornerstone of modern science, underpinning advances in medicine, biotechnology, and fundamental research that enable the creation of molecules that drive advancements in medicine, research, and technology.
Peptide Oligonucleotide Conjugates for Life Science Research
The conjugation of peptides to oligos is highly advantageous. It broadens their applications by enhancing them with additional unique properties. Read more.